Edwards Lifesciences Corporation $EW Shares Bought by Mirova US LLC

Key Points

• Mirova US LLC increased its stake in Edwards Lifesciences by 56.2% in Q2 2023, now owning approximately 2.93 million shares, which equates to 2.4% of its portfolio.
• Edwards Lifesciences reported a strong Q2 earnings with an EPS of $0.67, surpassing analysts' estimates, and recorded a revenue of $1.53 billion, up 11.9% year-over-year.
• The consensus rating for Edwards Lifesciences is a "Moderate Buy," with a target price of $87.06, reflecting multiple analysts' upgrades and downgrades in recent reports.

Mirova US LLC grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 56.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,931,297 shares of the medical research company's stock after acquiring an additional 1,054,301 shares during the quarter. Edwards Lifesciences comprises 2.4% of Mirova US LLC's portfolio, making the stock its 21st biggest position. Mirova US LLC owned about 0.50% of Edwards Lifesciences worth $229,257,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Allspring Global Investments Holdings LLC boosted its position in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences in the second quarter worth about $1,760,000. Czech National Bank boosted its position in shares of Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock worth $11,214,000 after buying an additional 7,917 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its position in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after buying an additional 370 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $76.70 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $64.51 and a fifty-two week high of $83.00. The business has a 50 day moving average price of $78.39 and a two-hundred day moving average price of $76.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.03 billion, a PE ratio of 11.04, a price-to-earnings-growth ratio of 3.68 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on EW. Truist Financial upped their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Saturday, September 27th. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Monday, September 29th. Finally, BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.